U.S. Markets closed

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
40.66+0.08 (+0.20%)
At close: 3:59PM EDT

40.66 +0.01 (0.02%)
After hours: 5:24PM EDT

People also watch
AZNNVSSNYLLYBMY
Full screen
Previous Close40.58
Open40.45
Bid40.66 x 2200
Ask40.67 x 5800
Day's Range40.40 - 40.69
52 Week Range37.20 - 44.54
Volume4,359,897
Avg. Volume2,761,704
Market Cap93.38B
Beta0.98
PE Ratio (TTM)40.42
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.99 (4.97%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters9 hours ago

    UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab

    The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday. The FDA's decision is in keeping with an advisory panel's recommendation in August that the FDA reject the drug. "We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab," He added that the company is seeking to "gain a full understanding of FDA requirements for U.S. approval" and plans to have a follow-up discussion with the agency.

  • Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
    Zacks3 days ago

    Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

    Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

  • Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
    Zacks4 days ago

    Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

    GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.